Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab) begin to dry up thanks to cheaper competitors.

AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.